col blocks we are bridge builder col blocks
COVID Antworten in den wissenschaftlichen Zeitschriften der Welt


40 Ergebisse       Seite 1

 [1] 
Elsevier: Molecular Therapy — Nucleic Acids
  Original Artikel Datum Titel Autoren   Alle Autoren
1 [GO] 2025―Jun―02 ACE-2 Blockade & TMPRSS2 Inhibition Mitigate SARS-CoV-2 Severity Following Cigarette Smoke Exposure in Airway Epithelial Cells In Vitro Shah S. Hussain, Emily Falk Libby, Jacelyn E. Peabody Lever, Jennifer L. Tipper, Scott E. Phillips, Marina Mazur, et al. (+4)
2 [GO] 2025―Mai―20 Delivery strategies for RNA-targeting therapeutic nucleic acids and RNA-based vaccines against respiratory RNA viruses: IAV, SARS-CoV-2, RSV Kinga Maziec, Agnieszka Baliga-Gil, Elzbieta Kierzek
3 [GO] 2025―Mai―14 Differentially expressed ncRNAs as key regulators in infection of human bronchial epithelial cells by the SARS-CoV-2 Delta variant Glory Ranches, Hubert Hackl, Viktoria Zaderer, Melanie Ploner, Wilfried Posch, Doris Wilflingseder, et al. (+2)
4 [GO] 2025―Mrz―31 Looking beyond the origin of SARS-CoV-2: Significant strategic aspects during the five-year journey of COVID-19 vaccine research and development Chiranjib Chakraborty, Yi-Hao Lo, Manojit Bhattacharya, Arpita Das, Zhi-Hong Wen
5 [GO] 2025―Mrz―25 mRNA-encoded ACE2 decoy lipid nanoparticles for neutralizing SARS-CoV-2 variants Lays Cordeiro Guimarães, Heloísa Athaydes Seabra Ferreira, Pedro Pires Goulart Guimarães
6 [GO] 2025―Mrz―20 Deciphering the NSP12/7/8 complex: Key insights into coronavirus replication and potential therapeutic targets Gao Luwen, Zhou Liyan, Abdul Rahman, Zulqarnain Baloch
7 [GO] 2025―Jan―30 COVID-19 mRNA vaccines are effective at stopping a nosy virus Uxue Beloki, Laura Salaberry, Carla Ortuño-Moya, Angie Molina, Cristian Smerdou
8 [GO] 2025―Jan―29 In vivo production of engineered ACE2 decoy protects lungs from SARS-CoV-2 infection Yuta Suzuki, Takayuki Miyazaki, Yoko Ida, Tatsuya Suzuki, Yumi Itoh, Shuto Nakao, et al. (+14)
9 [GO] 2025―Jan―18 Redefining NSP12 activity in SARS-CoV-2 and its regulation by NSP8 and NSP7 Deepa Singh, Tushar Kushwaha, Rajkumar Kulandaisamy, Vikas Kumar, Kamal Baswal, Saras H. Tiwari, et al. (+12)
10 [GO] 2024―Okt―16 mRNA vaccine-induced IgG mediates nasal SARS-CoV-2 clearance in mice Charlie Fricke, Lorenz Ulrich, Jana Kochmann, Janina Gergen, Kristina Kovacikova, Nicole Roth, et al. (+9)
11 [GO] 2024―Sep―10 Inhibition of SARS-CoV-2 growth in the lungs of mice by a peptide-conjugated morpholino oligomer targeting viral RNA Alexandra Sakai, Gagandeep Singh, Mahsa Khoshbakht, Scott Bittner, Christiane V. Löhr, Randy Diaz-Tapia, et al. (+18)
12 [GO] 2024―Aug―23 PLA-PEG as an alternative to PEGylated lipids for nanoparticle-based DNA vaccination against SARS-CoV-2 Walison Nunes da Silva, Pedro Henrique Dias Moura Prazeres, Pedro Pires Goulart Guimarães
13 [GO] 2024―Aug―15 Aptamer Decorated Nanocarriers for Viral Adsorption: a Special Look at COVID-19 Somayeh Handali, Mohsen Rezaei
14 [GO] 2024―Aug―15 Nanobody against SARS-CoV-2 non-structural protein Nsp9 inhibits viral replication in human airway epithelia Tomas Venit, Jeremy Blavier, Sibusiso B. Maseko, Sam Shu, Lilia Espada, Christopher Breunig, et al. (+6)
15 [GO] 2024―Jun―15 Unbiased plasma profiling using pre-selected RNA aptamer pools predicts mortality in COVID-19 and identifies protein risk-factors Asger Givskov Jørgensen, Daniel Miotto Dupont, Søren Fjelstrup, Claus Bus, Cecilie Bo Hansen, Thomas Benfield, et al. (+3)
16 [GO] 2024―Mai―24 A novel multitargeted self-assembling peptide-siRNA complex for simultaneous inhibition of SARS-CoV-2-host cell interaction and viral replication Martina Tuttolomondo, Stephanie Thuy Duong Pham, Mikkel Green Terp, Virginia Cendán Castillo, Nazmie Kalisi, Stefan Vogel, et al. (+6)
17 [GO] 2024―Feb―28 Exploring pulmoprotection in COVID-19: Moving toward microRNA-based theranostics Miron Sopic
18 [GO] 2024―Jan―10 MicroRNA-Centered Theranostics for Pulmoprotection in Critical COVID-19 Manel Perez-Pons, Marta Molinero, Iván D. Benítez, María C. García-Hidalgo, Shambhabi Chatterjee, Christian Ba¨r, et al. (+4)
19 [GO] 2023―Okt―25 Unveiling the role of PUS7-mediated pseudouridylation in host protein interactions specific for the SARS-CoV-2 RNA genome Roberto Giambruno, Elsa Zacco, Camilla Ugolini, Andrea Vandelli, Logan Mulroney, Manfredi D’Onghia, et al. (+11)
20 [GO] 2023―Aug―28 The current landscape of long COVID clinical trials: NIH’s RECOVER to Stanford Medicine’s STOP-PASC initiative Chiranjib Chakraborty, Manojit Bhattacharya
21 [GO] 2023―Jun―28 Molnupiravir’s mechanism of action drives “error catastrophe” in SARS-CoV-2: A therapeutic strategy that leads to lethal mutagenesis of the virus Srijan Chatterjee, Manojit Bhattacharya, Kuldeep Dhama, Sang-Soo Lee, Chiranjib Chakraborty
22 [GO] 2023―Apr―23 Self-replicating RNA nanoparticle vaccine elicits protective immune responses against SARS-CoV-2 Guibin Lin, Huan Yan, Jing Sun, Jincun Zhao, Yuan Zhang
23 [GO] 2023―Apr―06 Resistance to nirmatrelvir due to mutations in the Mpro in the subvariants of SARS-CoV-2 Omicron: Another concern? Srijan Chatterjee, Manojit Bhattacharya, Kuldeep Dhama, Sang-Soo Lee, Chiranjib Chakraborty
24 [GO] 2023―Mrz―15 Can the RBD mutation R346X provide an additional fitness to the “variant soup,” including offspring of BQ and XBB of SARS-CoV-2 Omicron for the antibody resistance? Srijan Chatterjee, Manojit Bhattacharya, Kuldeep Dhama, Sang-Soo Lee, Chiranjib Chakraborty
25 [GO] 2023―Feb―26 IPs-GRUAtt: An Attention Mechanism-Based Bidirectional Gated Recurrent Unit Network for Predicting Phosphorylation Sites of SARS-CoV-2 Infection Guiyang Zhang, Qiang Tang, Pengmian Feng, Wei Chen
26 [GO] 2023―Feb―14 Discovery of DNA aptamers targeting SARS-CoV-2 nucleocapsid protein and protein binding epitopes for label-free COVID-19 diagnostics Suttinee Poolsup, Emil Zaripov, Nico Hüttmann, Zoran Minic, Polina V. Artyushenko, Irina A. Shchugoreva, et al. (+3)
27 [GO] 2023―Feb―13 Natural selection of the D614G mutation in SARS-CoV-2 Omicron (B.1.1.529) variant and its subvariants Chiranjib Chakraborty, Abinit Saha, Manojit Bhattacharya, Kuldeep Dhama, Govindasamy Agoramoorthy
28 [GO] 2023―Jan―21 Broadly neutralizing aptamers to SARS-CoV-2: a diverse panel of modified DNA antiviral agents Amy D. Gelinas, Tiong Kit Tan, Sai Liu, Javier G. Jaramillo, James Chadwick, Adam C. Harding, et al. (+8)
29 [GO] 2022―Nov―02 Chimeric mRNA based COVID-19 vaccine induces protective immunity against Omicron and Delta variants Qidong Hu, Ying Zhao, Namir Shaabani, Xiaoxuan Lyu, Colin Powers, Haotian Sun, et al. (+19)
30 [GO] 2022―Aug―14 New Insights on Circular RNAs and Their Potential Applications as Biomarkers, Therapeutic Agents, and Preventive Vaccines in Viral Infections: with a glance at SARS-CoV-2 Nasim Rahmani-Kukia, Ardeshir Abbasi
31 [GO] 2022―Jul―13 Clinical Significance of Interferon Signaling Based on mRNA-microRNA Integration and Plasma Protein Analyses in Critically Ill COVID-19 Patients Yuki Togami, Hisatake Matsumoto, Jumpei Yoshimura, Tsunehiro Matsubara, Takeshi Ebihara, Hiroshi Matsuura, et al. (+7)
32 [GO] 2022―Jun―25 Cytokines and MicroRNAs in SARS-CoV-2: What do we know? Fahimeh Zamani Rarani, Bahman Rashidi, Mohammad Hassan Jafari Najaf Abadi, Michael R. Hamblin, Seyed Mohammad Reza Hashemian, Hamed Mirzaei
33 [GO] 2022―Jun―11 Serum microRNAs targeting ACE2 and RAB14 genes distinguish asymptomatic from critical COVID-19 patients Maria Calderon-Dominguez, Eva Trejo-Gutierrez, Almudena González-Rovira, Lucía Beltrán-Camacho, Marta Rojas-Torres, Sara Eslava-Alcón, et al. (+10)
34 [GO] 2022―Mrz―16 The accessible promoter-mediated supplementary effect of host factors provides new insight into the tropism of SARS-CoV-2 Guifang Du, Xiang Xu, Junting Wang, Xuejun Wang, Yang Ding, Fei Li, et al. (+6)
35 [GO] 2022―Feb―13 RIG-I-induced innate antiviral immunity protects mice from lethal SARS-CoV-2 infection Samira Marx, Beate M. Kümmerer, Christian Grützner, Hiroki Kato, Martin Schlee, Marcel Renn, et al. (+2)
36 [GO] 2021―Dez―31 SARS-CoV-2 Causes a Significant Stress Response Mediated by Small RNAs in the Blood of COVID-19 Patients Xi Liu, Yan-Zi Wen, Zi-Liang Huang, Xia Shen, Jun-Hao Wang, Yi-Hai Luo, et al. (+6)
37 [GO] 2021―Okt―22 Dual inhibition of TMPRSS2 and Cathepsin B prevents SARS-CoV-2 infection in iPS cells Rina Hashimoto, Ayaka Sakamoto, Sayaka Deguchi, Renxing Yi, Emi Sano, Akitsu Hotta, et al. (+3)
38 [GO] 2021―Sep―01 D614G mutation eventuates in all VOI and VOC in SARS-CoV-2: Is it part of the positive selection pioneered by Darwin? Chiranjib Chakraborty, Abinit Saha, Ashish Ranjan Sharma, Manojit Bhattacharya, Sang-Soo Lee, Govindasamy Agoramoorthy
39 [GO] 2021―Jun―24 A novel G-quadruplex aptamer-based spike trimeric antigen test for the detection of SARS-CoV-2 Ankit Gupta, Anjali Anand, Neha Jain, Sandeep Goswami, Anbalagan Ananthraj, Sharanabasava Patil, et al. (+6)
40 [GO] 2021―Jan―21 Small interfering RNA: a tailored approach to explore the therapeutic potential in COVID-19 Aditya Kiran Gatta, Venkata Rao Josyula
 [1] 

40 Ergebisse       Seite 1


[de][en]

Letzte Änderung 2023―Okt―27 12:08:13 UTC

© Daten-Quadrat 2022       Done in 0.005 sec